Filed Pursuant to Rule 424(b)(5)
                                                                    Registration
                                                                  No. 333-262551
PROSPECTUS SUPPLEMENT No. 1
(To the Prospectusdated February 11, 2022 and
the Prospectus Supplement, dated February 1, 2024)
                         INHIBIKASE THERAPEUTICS, INC.                          


                                 Up to $50,000                                  
                                  Common Stock                                  


We have entered into an At theMarket Offering Agreement, or the Sales 
Agreement, with H.C. Wainwright & Co., LLC, or Wainwright, relating to shares 
of our common stock offered by this prospectus supplement and the accompanying 
prospectus supplement datedFebruary 1, 2024 (the "February 1, 2024 
supplement") and prospectus dated February 11, 2022 (the "February 11, 2022 
prospectus"). In accordance with the terms of the Sales Agreement, we may 
offer and sell shares of ourcommon stock, $0.001 par value per share, from 
time to time through Wainwright acting as our agent (the "ATM Offering").
Our common stock islisted on The Nasdaq Capital Market under the symbol "IKT." 
On May 17, 2024, the last reported sale price of our common stock on The 
Nasdaq Capital Market was $1.73 per share.
We are filing this prospectus supplement to supplement and amend, as of May 
20, 2024, the accompanying February 1, 2024 supplement andFebruary 11, 2022 
prospectus to reduce the maximum aggregate gross sales price of our common 
stock that may be offered, issued and sold under the Sales Agreement from and 
after the date hereof to $50,000 (the "ATM Offering SizeReduction"), not 
including the shares of common stock previously sold. Under the February 1, 
2024 supplement, we initially registered up to $5,659,255 of our common stock 
for offer and sale pursuant to the Sales Agreement. As of the dateof the 
filing of this prospectus supplement, we have sold 315,338 shares of our 
common stock that are covered by the February 1, 2024 supplement pursuant to 
the Sales Agreement for an aggregate gross sales price of $849,187.85.
The purpose of this prospectus supplement is to update the accompanying 
February 1, 2024 supplement to reflect the ATM Offering Size Reduction. Except 
asmodified by this prospectus supplement, the terms of the ATM Offering remain 
unchanged, and the Sales Agreement remains in full force and effect.
Pursuant to General Instruction I.B.6 of Form
S-3,
in no event will we sell our common stock in a public primaryoffering with a 
value exceeding more than
one-third
of the aggregate market value of our voting and
non-voting
common equity held by
non-affiliates
in any
12-month
period as long as the aggregate market value of our outstanding voting and
non-voting
commonequity held by
non-affiliates
is less than $75,000,000.


Our business and aninvestment in our common stock involve significant risks. 
These risks are described under the caption "
Risk Factors
" beginning on
pages S-8
and 6 of the February 1, 2024 supplementand February 11, 2022 prospectus, 
respectively, and in the documents incorporated by reference into the February 
1, 2024 supplement and February 11, 2022 prospectus, as well as the risks and 
uncertainties described in other documentswe file with the Securities and 
Exchange Commission, or SEC.


Neither the SEC nor anystate securities commission has approved of anyone's 
investment in these securities or determined if this prospectus supplement, 
the February 1, 2024 supplement or the February 11, 2022 prospectus are 
truthful or complete. Anyrepresentation to the contrary is a criminal offense.



                              H.C.Wainwright & Co.                              
            The date of this prospectus supplement is May 20, 2024.             
{graphic omitted}